$NUVL

Flynn James E sold (to issuer) $2.1B of NUVL (indirect holdings)

Flynn James E sold (to issuer) 17,251,894 indirectly-held shares of Nuvalent, Inc. (NUVL) at $124.00 ($2.14B total) across 4 trades on 2026-07-15.

Original reporting
SEC EDGAR · Flynn James E
Published Jul 17, 2026, 7:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 7:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
medium confidence
Mentioned
$NUVL
Relevance
9/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

The newest concrete information is the disclosed sale size ($2.14B) and the $124/share price, which can influence short-term sentiment but does not, by itself, change operating fundamentals.

02

Market read

Traders may monitor for follow-on company actions (e.g., buyback-related flows) and for whether additional insider transactions occur, but the filing alone is not a fundamental catalyst.

03

What to watch

The filing notes no 10b5-1 plan and indirect holdings, so the economic interpretation depends on the underlying arrangement and whether other insiders or the company simultaneously executed related capital actions.

Relevance 9/10Novelty 4/10Timing: today’s SEC Form 4 filing (filed 2026-07-17)

Background

This is an SEC Form 4 insider transaction for Nuvalent, Inc. (NUVL) by director and 10% owner Flynn James E, reported as an indirect holding sale to the issuer.

Company-level read

Ticker impact

$NUVLNeutralMedium confidence
Context

Nuvalent director and 10% owner Flynn James E sold 17,251,894 shares to the issuer at $124/share for about $2.14B, leaving 0 shares.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than fundamentals unless tied to a broader capital return or financing plan.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size and price, but it provides no explicit reason, no 10b5-1 plan, and no accompanying company guidance or operational change.

Market effects

No sector read-across is provided; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is to the issuer, it may be part of a structured capital return (for example, buyback participation) rather than a negative view on the business.

Key entities

  • Nuvalent, Inc.

    Subject of the Form 4 insider transaction; director and 10% owner sold shares to the issuer at $124/share.

  • Flynn James E

    Director and 10% owner who sold 17,251,894 shares (indirect holdings) and reported 0 shares after the transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.